This is therefore a contrasting of the analyst recommendations, profitability, risk, dividends, institutional ownership, earnings and valuation in Rhythm Pharmaceuticals Inc. (NASDAQ:RYTM) and Paratek Pharmaceuticals Inc. (NASDAQ:PRTK). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rhythm Pharmaceuticals Inc.	N/A	0.00	74.06M	-2.05	0.00
Paratek Pharmaceuticals Inc.	17.12M	10.15	112.36M	-3.64	0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Rhythm Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc.

Profitability

Table 2 shows Rhythm Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

	Net Margins	Return on Equity	Return on Assets
Rhythm Pharmaceuticals Inc.	0.00%	-28.4%	-27.5%
Paratek Pharmaceuticals Inc.	-656.31%	-132.5%	-44.6%

Liquidity

35.4 and 35.4 are the respective Current Ratio and a Quick Ratio of Rhythm Pharmaceuticals Inc. Its rival Paratek Pharmaceuticals Inc.’s Current and Quick Ratios are 11.4 and 11.4 respectively. Rhythm Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Paratek Pharmaceuticals Inc.

Analyst Ratings

The Ratings and Recommendations for Rhythm Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc. are featured in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Rhythm Pharmaceuticals Inc.	0	0	0	0.00
Paratek Pharmaceuticals Inc.	0	0	4	3.00

Meanwhile, Paratek Pharmaceuticals Inc.’s consensus target price is $21.25, while its potential upside is 296.46%.

Insider and Institutional Ownership

The shares of both Rhythm Pharmaceuticals Inc. and Paratek Pharmaceuticals Inc. are owned by institutional investors at 93.7% and 77.7% respectively. Insiders owned 11.2% of Rhythm Pharmaceuticals Inc. shares. Comparatively, insiders own roughly 3.1% of Paratek Pharmaceuticals Inc.’s shares.

Performance

In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Rhythm Pharmaceuticals Inc.	-2.83%	7.03%	-2.63%	-12.72%	12.22%	5.92%
Paratek Pharmaceuticals Inc.	-6.09%	0.67%	-8.98%	-32.44%	-46.95%	32.36%

For the past year Rhythm Pharmaceuticals Inc. was less bullish than Paratek Pharmaceuticals Inc.

Summary

On 6 of the 10 factors Rhythm Pharmaceuticals Inc. beats Paratek Pharmaceuticals Inc.

Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes peptide therapeutics for the treatment of rare genetic disorders of obesity in the United States. Its lead product candidate is Setmelanotide, a melanocortin-4 receptor agonist that is in Phase III clinical trials for treating POMC deficiency obesity and leptin receptor deficiency obesity; and Phase II clinical trials for treating Bardet-Biedl syndrome, Alström syndrome, POMC heterozygous deficiency obesity, and POMC epigenetic disorders. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts. Rhythm Pharmaceuticals, Inc. is a subsidiary of Motus Therapeutics, Inc.

Paratek Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical stage for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trial for the treatment of acne and rosacea. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III studies for ABSSSI and CABP. It has collaborative research and license agreement with Allergan plc to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and license agreement with Shin Nippon Biomedical Laboratories Ltd. to develop TO-2070 for the treatment of acute migraine. The company also has a cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.